Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade

Leukemia Research

Volumn 33, Issue 3, 2009, Pages 460-464

  Pallasch, Christian P ^a   Ulbrich, Sabine ^a   Brinker, Reinhild ^a   Hallek, Michael ^a   Uger, Robert A ^b   Wendtner, Clemens Martin ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Trillium Therapeutics Inc   (Canada)

Author keywords

CD200; Chronic lymphocytic leukemia; Fibromodulin; Regulatory T cells; Tumor associated antigen

Indexed keywords

CD200 ANTIGEN; CD40 LIGAND; FIBROMODULIN; IMMUNOSUPPRESSIVE AGENT;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CD4+ CD25+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FOXP3+ T LYMPHOCYTE; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CELL PROLIFERATION; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEOGLYCANS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 58549108182     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.08.021     Document Type: Article

References (20)

1. Caligaris-Cappio F., and Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17 (1999) 399-408
2. Gorgun G., Holderried T.A., Zahrieh D., Neuberg D., and Gribben J.G. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115 (2005) 1797-1805
3. Gorczynski R.M. CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 6 (2005) 483-488
4. McWhirter J.R., Kretz-Rommel A., Saven A., Maruyama T., Potter K.N., Mockridge C.I., et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103 (2006) 1041-1046
5. Kretz-Rommel A., Qin F., Dakappagari N., Cofiell R., Faas S.J., and Bowdish K.S. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 180 (2008) 699-705
6. reg using monoclonal antibodies to CD200R. Transplantation 79 (2005) 1180-1183
7. Mayr C., Bund D., Schlee M., Moosmann A., Kofler D.M., Hallek M., et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 105 (2005) 1566-1573
8. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., et al. CD200 is a new prognostic factor in multiple myeloma. Blood 108 (2006) 4194-4197
9. Tonks A., Hills R., White P., Rosie B., Mills K.I., Burnett A.K., et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21 (2007) 566-568
10. Mayr C., Bund D., Schlee M., Bamberger M., Kofler D.M., Hallek M., et al. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol 34 (2006) 44-53
11. Petermann K.B., Rozenberg G.I., Zedek D., Groben P., McKinnon K., Buehler C., et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Investig 117 (2007) 3922-3929
12. Longo P.G., Laurenti L., Gobessi S., Sica S., Leone G., and Efremov D.G. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111 (2008) 846-855
13. Trojan A., Schultze J.L., Witzens M., Vonderheide R.H., Ladetto M., Donovan J.W., et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6 (2000) 667-672
14. Wendtner C.M., Kofler D.M., Theiss H.D., Kurzeder C., Buhmann R., Schweighofer C., et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 100 (2002) 1655-1661
15. Gitelson E., Hammond C., Mena J., Lorenzo M., Buckstein R., Berinstein N.L., et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 9 (2003) 1656-1665
16. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., and Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96 (2000) 2917-2924
17. Mayr C., Kofler D.M., Buning H., Bund D., Hallek M., and Wendtner C.M. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood 106 (2005) 3223-3226
18. Gorczynski R.M., Chen Z., Hu J., Kai Y., and Lei J. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin Exp Immunol 126 (2001) 220-229
19. reg using monoclonal antibodies to CD200R. Transplantation 79 (2005) 488-491
20. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (2005) 2018-2025